Novartis books $1.9 billion impairment, lifts full-year guidance
Novartis recorded a $1.9 billion partial impairment charge in the third quarter tied to del-desiran, the myotonic dystrophy candidate it acquired thro
Novartis
Every Fin-node story mentioning Novartis — 2 stories, newest first.
Novartis · 2 stories
Novartis pays $7.8 billion for Abogen mRNA asset
Novartis agreed to pay up to $7.8 billion for global rights to an early-stage mRNA therapy from China's Abogen Biosciences, the latest and largest in